Loading
HKSEHealthcareBiotechnology
Latest quote
HK$28.20
−HK$0.80 · -2.76%
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Latest quote
HK$28.20
−HK$0.80 · -2.76%
Regular session · HKT · Market data may be delayed.
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Day range
Current HK$28.20
52-week range
Current HK$28.20
Regular session · HKT · Market data may be delayed.
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Day range
Current HK$28.20
52-week range
Current HK$28.20
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 14.1B CNY | 12.28B CNY | 11.54B CNY | 10.27B CNY | 7.44B CNY |
| Cost of goods sold | 9.19B CNY | 8.07B CNY | 7.41B CNY | 6.5B CNY | 4.76B CNY |
| Gross profit | 4.91B CNY | 4.2B CNY | 4.12B CNY | 3.77B CNY | 2.68B CNY |
| Research and development | 576.02M CNY | 469.26M CNY | 448.28M CNY | 282.32M CNY | 151.77M CNY |
| Selling, general, and administrative | 788.7M CNY | 720.5M CNY | 1.86B CNY | 969.49M CNY | 410.44M CNY |
| Operating expenses | 2.98B CNY | 2.1B CNY | 2.28B CNY | 2.02B CNY | 1.15B CNY |
| Interest income | 39.39M CNY | 73.63M CNY | 29.93M CNY | 35.21M CNY | 64.41M CNY |
| Interest expense | 192.81M CNY | 243.72M CNY | 182.19M CNY | 167.31M CNY | 83.07M CNY |
| Depreciation and amortization | 1.18B CNY | 1.05B CNY | 927.17M CNY | 696.18M CNY | 497.92M CNY |
| Operating income | 1.93B CNY | 2.1B CNY | 1.85B CNY | 1.69B CNY | 1.91B CNY |
| Net income | 1.66B CNY | 1.79B CNY | 1.6B CNY | 1.37B CNY | 1.66B CNY |
Company facts updated Sep 7, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.2188
2025 complete year+35.7% since 2021
2026 partial: HK$0.2299
HK$0.1612
2,021
HK$0.3522
2,022
HK$0.3286
2,023
HK$0.2199
2,024
HK$0.2188
2,025
HK$0.2299
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 7, 2026 | HK$0.2299Annual | Jul 8, 2026 | Aug 7, 2026 |
Dividend | Jul 4, 2025 | HK$0.2188Annual | Jul 7, 2025 | Aug 6, 2025 |
Dividend | Jun 27, 2024 | HK$0.2199Annual | Jun 28, 2024 | Jul 26, 2024 |
Dividend | Jul 18, 2023 | HK$0.3286Annual | Jul 19, 2023 | Aug 18, 2023 |
Dividend | Jun 6, 2022 | HK$0.5283Annual | Jun 7, 2022 | Jul 12, 2022 |
Dividend | Jun 1, 2021 | HK$0.3626Annual | Jun 2, 2021 | Jul 15, 2021 |
Ex-dividend Jul 7, 2026
HK$0.2299
Annual
Record Jul 8, 2026 · Payment Aug 7, 2026
Ex-dividend Jul 4, 2025
HK$0.2188
Annual
Record Jul 7, 2025 · Payment Aug 6, 2025
Ex-dividend Jun 27, 2024
HK$0.2199
Annual
Record Jun 28, 2024 · Payment Jul 26, 2024
Ex-dividend Jul 18, 2023
HK$0.3286
Annual
Record Jul 19, 2023 · Payment Aug 18, 2023
Ex-dividend Jun 6, 2022
HK$0.5283
Annual
Record Jun 7, 2022 · Payment Jul 12, 2022
Ex-dividend Jun 1, 2021
HK$0.3626
Annual
Record Jun 2, 2021 · Payment Jul 15, 2021
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS14.99M0.00%646.2B USD0.05%$88.41+0.50%
Vanguard FTSE Emerging Markets ETFVWO14.8M0.01%162.3B USD0.06%$61.44+0.74%
Vanguard FTSE All-World ex-US ETFVEU2.49M0.00%95.9B USD0.04%$86.41+0.54%
Schwab Emerging Markets Equity ETFSCHE1.57M0.01%12.94B USD0.06%$37.58+0.75%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM1.27M0.01%9.54B USD0.39%$41.00+1.36%
Vanguard Total World Stock ETFVT847.95K0.00%97.9B USD0.06%$161.73-0.02%
WisdomTree China ex-State-Owned Enterprises FundCXSE847.32K0.18%478.55M USD0.32%$37.3839+0.41%
Dimensional World ex U.S. Core Equity 2 ETFDFAX687.64K0.01%12.55B USD0.28%$38.61+0.44%Vanguard Total International Stock ETFVXUSVanguard FTSE Emerging Markets ETFVWOVanguard FTSE All-World ex-US ETFVEUSchwab Emerging Markets Equity ETFSCHEDimensional - Emerging Markets Core Equity 2 ETFDFEMVanguard Total World Stock ETFVTWisdomTree China ex-State-Owned Enterprises FundCXSEDimensional World ex U.S. Core Equity 2 ETFDFAXAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
